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Abstract
Background: There have been many changes in clinical trials methodology since the introduction of lithium and the
beginning of the modern era of psychopharmacology in 1949. The nature and importance of these changes have not been
fully addressed to date. As methodological flaws in trials can lead to false-negative or false-positive results, the objective of
our study was to evaluate the impact of methodological changes in psychopharmacology clinical research over the past 60
years.
Methodology/Principal Findings: We performed a systematic review from 1949 to 2009 on MEDLINE and Web of Science
electronic databases, and a hand search of high impact journals on studies of seven major drugs (chlorpromazine, clozapine,
risperidone, lithium, fluoxetine and lamotrigine). All controlled studies published 100 months after the first trial were
included. Ninety-one studies met our inclusion criteria. We analyzed the major changes in abstract reporting, study design,
participants’ assessment and enrollment, methodology and statistical analysis. Our results showed that the methodology of
psychiatric clinical trials changed substantially, with quality gains in abstract reporting, results reporting, and statistical
methodology. Recent trials use more informed consent, periods of washout, intention-to-treat approach and parametric
tests. Placebo use remains high and unchanged over time.
Conclusions/Significance: Clinical trial quality of psychopharmacological studies has changed significantly in most of the
aspects we analyzed. There was significant improvement in quality reporting and internal validity. These changes have
increased study efficiency; however, there is room for improvement in some aspects such as rating scales, diagnostic criteria
and better trial reporting. Therefore, despite the advancements observed, there are still several areas that can be improved
in psychopharmacology clinical trials.
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Introduction
Clinical trials gained importance in medical research after
World War II, when there was a rapid increase in drug
development and research. Psychopharmacology is a field that
reflects the marked increase in using clinical trials. In fact, the
modern era of psychopharmacology began only in 1949, when
lithium was reintroduced in psychiatry [1], being followed by the
release of chlorpromazine (1954), imipramine (1958) and several
others. These new drugs brought dramatic modifications in
psychiatric practice and research as a new study methodology
had to be developed for a field that was, until then, virtually absent
from pharmacological therapies. Products of this new methodol-
ogy included the development of severity rating scales and new
diagnostic criteria, which eventually led to the third and fourth
editions of the Diagnostic and Statistical Manual of Mental
Disorders (DSM) [2]. Meanwhile, medical clinical research itself
also experienced advancements such as novel study designs, better
methods of blinding and randomization, more sophisticated
statistical methods and better definition of outcomes [3].
Presently, psychiatric research faces important challenges. For
instance, although psychiatric drugs have distinct mechanisms of
action, they seem to have the same efficacy in clinical trials [4].
Moreover, the assessment of outcomes is mostly based upon
severity scales that are somewhat subjective [5]. Another issue is
that the diagnostic criteria are ‘‘operational’’, meaning that a
minimum appearance of symptoms are required to fulfill a
diagnosis, which does not always reflect clinical practice [6].
Consequently, there is a concern whether psychiatric clinical
trials are methodologically adequate and, if not, which aspects of
trial design should be further improved [7]. Therefore, it is
important to analyze the change of these aspects over time in
order to understand our current methodological practice and
also to be able address whether the results of past trials, which in
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more recent clinical studies in psychopharmacology are failing to
achieve positive results, new paths for clinical trial design are
needed [7].
Therefore, a critique overview of the methodology used in past
and current clinical trials can advance psychopharmacologic
research. Our aim is to examine the major changes in clinical trial
design by reviewing selected studies published in high-impact
journals over the past sixty years. The purpose of our study is to
work towards providing a better understanding on the develop-
ment of psychopharmacological clinical trials, and thereby
identifying future directions for its continuous advancement.
Methods
Eligibility Criteria
Because a review of all psychopharmacological drug clinical
trials over the past sixty years is unfeasible, we reviewed only
studies published in high-impact, influential general medical (The
New England Journal of Medicine [NEJM], JAMA, Lancet and
British Medical Journal) and psychiatric journals (Archives of
General Psychiatry, The American Journal of Psychiatry [AJP],
The Journal of Mental Sciences/British Journal of Psychiatry
[BJP] and The Journal of Clinical Psychiatry [JCP]). It would also
be unfeasible to review all of the available drugs currently and ever
used in psychiatry; therefore we looked for important psychiatric
drugs developed at different time periods that: (1) are currently
used in psychiatry (for ease of interpretation of results); (2) are used
in psychotic, mood or anxiety disorders (since such disorders rely
significantly on psychopharmacological therapies) and (3) were
introduced in different time periods as to cover the time period
reviewed. The selected drugs were: lithium (most effective and
frequently used drug for bipolar disorder) [8]; chlorpromazine (one
of the most important drugs in the history of psychiatry) [9];
diazepam (the most used benzodiazepinic drug) [10]; clozapine
(the most effective antipsychotic drug to date) [11]; fluoxetine (the
prototypical, most studied antidepressant) [12]; risperidone (the
first second-generation antipsychotic introduced) [13]; and
lamotrigine (the first drug FDA approved for maintenance
treatment of bipolar disorder since lithium) [14].
We also looked only for studies published within 100 months
after the first retrieved article, when efficacy studies are typically
conducted. The exceptions were lithium and clozapine, in which
we expanded the search to twenty years, as such drugs were not
initially available in the U.S. due to several deaths initially
reported related to their non-monitored use [15]. Here, it should
be underscored that three possible strategies were considered in
our study: (1) to review all studies over 60 years on one drug only;
(2) to review all studies on one mental condition only; (3) the
present strategy. However, the first strategy would hinder the
review of newer drugs, while older drugs are currently seldom
researched for efficacy The second strategy premises diagnostic
stability criteria over time, which is invalid: in 60 years, there were
4 Diagnostic and Statistical Manual of Mental Disorders (DSM) and 5
International Classification of Diseases (ICD) with different diagnostic
nomenclatures. For instance, the current diagnostic of major
depressive disorder did not exist in DSM-II in which depressed
patients would probably be diagnosed as depressive neurosis;
involutional melancholia; manic-depressive illness, depressed type; or
neurasthenic neurosis [16]. Moreover, there is no single diagnosis
for which different drugs were tested in efficacy trials for this entire
period. Finally, the present strategy allowed us to consider several
drugs and diagnoses thus extending the scope of this review
examining changes over time.
Search and Collection of the Data
Our search strategy is shown in Figures 1, 2 and 3. We
considered the following databases: MEDLINE, Web of Science,
Cochrane and EMBASE. For drugs introduced before 1970, the
first author (ARB) also searched on the web sites of the journals
containing past issues. The first (ARB) and the second (LT) author
also performed hand search in the libraries of University of Sao
Paulo Medical School and Harvard Medical School (Countway
Medical Library), respectively. Finally, ARB and LT examined
reference lists in systematic reviews and retrieved papers and
contacted experts on the field. The keywords used for each drug
review was the name of the drug, limited by the time period and
by the referred journals (Figures 1, 2, 3). The procedures carried
out in this review are consistent with the Cochrane guidelines for
reporting systematic reviews and meta-analyses [17] and also with
the QUOROM guidelines (Table S1).
The inclusion criteria for each drug were: (1) clinical studies on
anxious, mood or psychotic disorders; (2) all controlled, random-
ized, interventional trials, whether testing either drug therapeutic
or prophylactic properties (i.e., response/remission or relapse/
recrudescence). We excluded: (1) other designs, such as case
reports, case series, observational designs or quasi-experimental
studies; (2) studies whose primary aim was not to test drug efficacy
(e.g., psychometric studies); (3) clinical trials performed for other
conditions than specified (e.g. lithium in hyperactive children)
[18]); and (4) studies in animals. Since all selected journals are
published in English, language restriction was not an issue.
Data Extraction
The first author (ARB) performed the data extraction and
compiled the variables extracted to the database, while the second
author (LT) checked if data were correctly recorded. The third
author (FF) reviewed a random sample of the articles to recheck
for errors in data extraction or interpretation. Disagreements were
resolved by consensus. We designed a semi-structured checklist,
based on previous methodological reviews of clinical trials
[19,20,21,22,23] to address the following aspects:
(1) general characteristics (author names, publication year, journal
published and sources of financial support);
(2) abstract reporting, in which the complete report of background,
methods and results in the abstract (yes/no for each one) were
considered;
(3) study design, assessing number of centers (uni- vs. multicentric),
use of washout (yes vs. no vs. drug-free), use of placebo arm
(yes vs. no), study design (2-arm vs. 3-arm vs. other designs), use
of intention-to-treat analysis (yes vs. no);
(4) participants section, assessing the sample size, the reporting of
informed consent (yes vs. no) and eligibility criteria (clear vs.
unclear), the method for evaluating diagnostic severity
(personal judgment vs. rating scales) and for confirming the
diagnostic (clinical interview vs. structured questionnaires);
(5) methods section, assessing whether the method of randomization
reported was adequate vs. inadequate vs. biased; the method
for allocation concealment (adequate vs. inadequate vs.
biased); sample size calculation reporting (yes vs. no); and
statement of primary hypothesis (adequate vs. inadequate);
(6) results reporting, assessing the reporting of baseline comparisons
(adequate vs. inadequate), of adverse effects (adequate vs.
inadequate) and of dropout reasons (adequate vs. inadequate);
and the use of parametric tests (yes/no).
(7) conclusion section, assessing whether the trial was reported as
positive vs. negative vs. unclear; and whether the conclusions
Overview of Clinical Trials
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inconsistent vs. dubious).
The criteria used for data classification are presented in Table 1.
Data Analysis
The variables collected were managed as outcome variables and
each one was analyzed separately. ‘‘Year’’ was the main predictor
variable as to assess whether the outcome changed over time. We
performed a separate analysis using drug class (3 levels:
antipsychotics – clozapine, chlorpromazine and risperidone; mood
stabilizers – lamotrigine and lithium; and others – fluoxetine and
diazepam) as to assess a possible drug class confounding effect.
‘‘Year’’ was treated as a continuous and an ordinal variable
(divided in equal quartiles). When treated as continuous, logistic
regressions were applied; when ordinal, we used the chi-square or
the Fisher’s exact test. Analyses were performed using Stata
statistical software, version 9.0 (StataCorp, College Station, TX,
USA) and SPSS Software, version 16. As shown below, analyses
using both methods yielded quite similar results.
Results
Ninety-one articles were reviewed, 24 (26.7%) on chlorprom-
azine, 20 (21%) on lithium, 8 (8.9%) on diazepam, 6 (6.7%) on
clozapine and lamotrigine each, 16 (17.8%) on fluoxetine and 11
(12.2%) on risperidone. Most trials were published in the BJP (30
trials, 33%), the JCP (20 trials, 22%) and the AJP (19 trials, 21%).
We did not identify any trials from NEJM. Twenty- four trials
were performed in 1961 or earlier, 23 trials throughout 1962–74,
22 trials throughout 1975–89 and 22 trials from 1990 to 2003.
Also, we were not able to identify the major source of sponsorship
in 48 (52%) of the studies. In 36 studies, we classified the
sponsorship as public while in 7 the classification was considered
private. The issue here is that newer trials have many authors and
each one usually has one or more funding source. For example,
one article [24] reported funding from a NIH grant, two
foundations award grants, and a public, local mental health grant.
The first author was a member of the speaker’s bureau for four
pharmaceutical companies, one of them being the sponsor of the
tested drug. In such cases, we classified the sponsorship as
‘‘unclear’’. As this issue occurred in 52% of the studies, we did not
perform further statistical analyses.
The individual characteristics of each trial are presented in the
Appendix (Table S2). Table 2 presents the summary character-
istics of the reviewed studies. Table 3 shows the analyses run for
categorical variables.
Regarding abstract reporting, there was an improvement in
quality reporting in all sections of an abstract (background,
methods and results) over time (p,0.01 for all analyses)
(Figure 4).
Figure 1. Flow chart for the selection of Risperidone and Fluoxetine studies.
doi:10.1371/journal.pone.0009479.g001
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ment in clear eligibility criteria (p,0.01). Examples of unclear
eligibility criteria were: ‘‘anxiety enough to require a tranquilizer’’
(comparing Diazepam and Lorazepam) [25]; ‘‘the most aggressive
and disturbed untreated patients’’ (comparing Chlorpromazine
and Prochlorpromazine)[26]; ‘‘patients needing ECT’’ (comparing
Diazepam and Amitryptyline) [27]; and ‘‘when chlorpromazine
was [considered] the treatment of choice’’ (comparing Chlor-
promazine and ‘Pacatal’). Also, newer trials used more structured
interviews to confirm a diagnosis, while older trials relied mainly
on clinical interviews (p,0.01). Accordingly, newer trials used
severity rating scales more frequently than older trials, which
assessed severity based on physician’s judgment (p,0.01). A
performance bias was also possible as the raters were not blinded
to the interventions what could theoretically favors the experi-
mental arm in some of the studies. It was also noticed that newer
trials performed or reported more sample size calculations than
older trials (p,0.01). The sample sizes of newer studies were
marginally larger (p=0.04 and 0.03 for year as continuous and as
ordinal, respectively) than older studies; however this difference
could be explained by a recent (1995) trial [28] that is twice as
large as compared to next largest study [29]. Finally, newer trials
reported or used more informed consents than the older trials
(p,0.01). Signs of poor ethical standards were observed in some of
the older trials. For example, in one relapse trial of lithium vs.
placebo for maniac-depressive illness, ambulatory patients had
their drug changed to placebo without knowing [30].
Regarding study design, a two-arm, parallel design was most
often used in newer trials, when compared to the three-arm and
other designs (p,0.01) (Figure 5). The number of studies using
placebo arms did not change over time (p=0.13 for year as
continuous and ordinal). Newer studies were also associated with
multicentric designs, drug washout prior to the trial onset, and
intention-to-treat analyses (p,0.01for all variables) (Figure 6).
We noticed that six studies reported clearly biased methods of
randomization and allocation: alternated admission in the ward
[31], using 25 red and 25 black cards for group assignment [32],
physician’s judgment on the best therapy (insulin coma or
chlorpromazine) [33]; randomization and assignment performed
by the hospital pharmacist, ‘‘the choice having been made by him at
random’’, although 45 patients received active drugs and 25 control
tablets [34]; assignment according to the patient willingness to do
weekly blood tests (mandatory when taking clozapine) [35]; and
physician’s judgment on the best therapy (olanzapine or
risperidone) [36]. In these cases, although the methods were
reported, we considered them as ‘‘inadequate’’ and were analyzed
accordingly. The results showed that the reporting of sequence
generation methods improved over time (p=0.01 and p,0.01 for
year as continuous and as ordinal, respectively) while the
allocation concealment did not (p=0.39 and p=0.08 for year as
Figure 2. Flow chart for the selection of Clozapine and Lamotrigine studies.
doi:10.1371/journal.pone.0009479.g002
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number of trials reporting the randomization and allocation
methods was low (18% and 10%, respectively). Also, eight trials
were not double-blinded or single-blinded with external raters,
four of them compared patients using pharmacological vs. non-
pharmacological treatments (ECT, insulin therapy or psychother-
apy) [31,33,37,38]. One used a no-treatment arm [39], one was
initially double-blinded but patients and physicians discovered the
assignment because the pills taken differed in color, size and
quantity for each arm [32], one had patients in one group doing
weekly blood tests while the other group did not [35]; and in
another study, patients knew their assignment groups [36]. The
other 83 trials used double-blinded or ‘‘double-dummy’’ tech-
niques. Figure 7 visually assesses these changes.
Regarding the results section, newer trials adequately reported
more than older trials: ‘‘baseline group comparisons’’ (p,0.01),
‘‘adverse effects’’ of drugs (p,0.01) but not ‘‘reasons for drop-
outs’’ (p=0.34 and p=0.41 for year as continuous and ordinal,
respectively). Also, newer trials reported more than older trials the
p statistics (p,0.01) and used more parametric tests (p,0.01).
In the conclusion section we assessed whether the results were
presented as positive, negative or did not provide a clear
statement. We also recorded whether or not the conclusion is
supported by the results; accordingly to our previous definitions
(Table 1). Some examples of the 35 trials classified as ‘‘dubious’’
were: a lamotrigine vs. placebo trial that concluded the active drug
‘‘is associated with superior efficacy’’ although this was true for
some but not all analyses [40]; and a trial comparing acetophe-
nazine vs. diazepam in anxious depression that reported several
comparisons and was not able to conclude which one was better
[41]. Examples of inconsistent conclusions were: a underpowered
trial that compared lithium vs. chlorpromazine in 23 patients with
mania that concluded that ‘‘lithium is apparently superior (…) in
mania’’. Although the author reported that ‘‘lithium was superior
on all scales, this was not statistically significant on any(…)’’. He
explained his conclusion arguing that ‘‘in this study and all
previous ones these findings are based on poor methodological
techniques…. due to the nature of the illness and the [nature of]
the drugs, no reasonable (…) trial can ever be performed’’ [42];
and a 1959 trial in which the author compared the effects of 4
drugs in geriatric patients with various diagnostics – his severity
assessment was based on four dimensions (social, intellectual,
mood and thought improvement) and included his clinical
evaluation, a psychologist evaluation and the ‘‘nurses and
psychiatric aides’’ evaluation performed two times a week for 18
weeks. At the end, though, the author stated that ‘‘since it was
impossible quantitatively to weigh these fluctuating factors, the
final judgment in assessing the patient’s responses was necessarily a
clinical decision based on the accumulated data’’ [43]. Impor-
tantly, the 12 studies rated as ‘‘inconsistent’’ had some signs of
Figure 3. Flow chart for the selection of Chlorpromazine, Lithium and Diazepam studies.
doi:10.1371/journal.pone.0009479.g003
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the gender proportion, 3 did not report the mean age of the
subjects, none used intention-to-treat, 10 had unclear eligibility
criteria, 9 did not report randomization methods and 10 did not
state detailed adverse effects.
We observed that newer trials showed more conclusions
consistent with results (when compared to dubious or inconsistent)
than older trials (p,0.01), an association that remained significant
when the variable ‘‘positive or negative results’’ was inputted in the
model (p,0.01). Also, we did not observe a particular trend in
more positive results (as compared to negative or unclear results)
over time (p=0.16) (Figures 8, 9 and 10).
Finally, we ran separate analyses for drug class to address
whether it could explain the differences observed. Of the 24
analyses performed, we observed associations between the drug
class ‘‘other’’ and the variables informed consent (p=0.01), use of
placebo (p=0.01), randomization (p=0.02), allocation (p=0.02),
baseline comparison (p=0.04) and consistency of results (p,0.01);
although in all cases the difference was significant only for the
group ‘‘others’’ that enrolled fluoxetine and diazepam, not
properly showing a ‘‘drug class effect’’. Also, since the results
were only marginally significant, they are probably false-positive
findings.
Discussion
Our results show that the methodology of clinical trials changed
substantially over the past 60 years, with significant improvement
in quality reporting and in internal validity. The gains in quality
reporting were observed in abstract reporting, in which we
observed more complete reports in all subsections (background,
methods and results) over time. Improvement was also observed in
results reporting – as p values, effect sizes, baseline group
comparisons and adverse effects were more completely reported
Table 1. Criteria used for data classification in the present review.
Abstract Reporting Background Adequate - when a synthesis of the current knowledge and study objectives was provided.
Methods Adequate - when the trial design, the subjects, and the interventions were described.
Results Adequate - when the results, the primary outcome and the main conclusions were described.
Study design Wash-out Yes - if prior treatments were withdrawn before the trial started.
Intention to treat Yes - if the analysis considered the entire sample, before dropouts.
Sample Size Calculation Yes - if an analysis for sample size was performed and presented.
Informed consent Yes - if the use of an informed consent is described.
Subjects Eligibility criteria Clear - the study population can be reproducible with the information given.
Unclear - The study population cannot be reproducible and/or there is evidence of enrollment bias.
Diagnostic Criteria Clinical interview - the diagnostic was confirmed by a clinical interview.
Structured form - the diagnostic was confirmed by using an structured questionnaire.
Diagnostic Severity Rating scales - when rating scales were used to assess severity.
Physician judgment - when the physician judged the degree of improvement and/or severity.
Methods Randomization Adequate - when the method of sequence generation was reported.
Inadequate - when the sequence generation method was not reported.
Evidence of bias - when the method was described but it was biased.
Allocation Adequate - when the method of allocation concealment was reported.
Inadequate - when the allocation concealment method was not reported.
Evidence of bias - when the method was described but it was biased.
Primary Hypothesis Adequate - the primary hypothesis was clearly stated.
Inadequate - the primary hypothesis was not or was incompletely stated.
Results Baseline Comparisons Adequate - when the groups were compared at baseline.
Inadequate - when the groups were not compared at baseline.
Adverse Effects Adequate - the adverse effects were fully reported.
Inadequate - the adverse effects were not or were partially reported.
Dropout reasons Adequate - the reasons of dropouts were assessed and presented.
Inadequate - the dropout reasons were not presented or not fully reported.
p value Adequate - the p value of the primary outcome was reported.
Conclusion Trial result Positive - the authors stated their main hypothesis was proved.
Negative - the authors stated they failed to prove their main hypothesis.
Unclear - the authors does not clear state whether or not their main hypothesis was proved.
Consistency Yes - the conclusion is supported by the study results.
Dubious - lack of trial quality or overinterpretation of results.
No - There is clear evidence of bias in the study or the conclusion is clearly not coherent with the
results shown.
doi:10.1371/journal.pone.0009479.t001
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used more explicit eligibility criteria, objective rating scales,
intention-to-treat analyses. Newer studies also showed less biased
methods of randomization and blinding. Accordingly, the
conclusion of the results of newer studies were more appropriate
and consistent than older trials. Study design also changed in some
aspects over time: sample size increased, more studies performed
(or reported) sample size calculations, and 2-arm substituted 3-or-
Table 2. Shows the summary characteristics of the studies.
Time Period 1961 and earlier 1962–1974 1975–1989 1990 and after
General characteristics
Number of trials 24 23 22 22
Drug class Antipsychotic 24 0 4 13
Mood Stabilizer 0 15 5 6
Other 0 8 13 3
Disorder Psychosis (*) 23 0 3 12
Affective disorders (**) 0 16 4 6
Anxiety disorders 1 7 0 2
Unipolar depression 0 0 15 2
Centers Multicentric 3 8 6 15
Number of subjects Mean (SE) 120 (30) 69 (14) 86 (15) 214 (65)
Abstract
Background Adequate 2 2 8 17
Methods Adequate 8 14 14 21
Results Adequate 5 5 8 21
Study design
Wash-out Reported 4 2 12 17
Intention-to-treat Performed 0 1 4 16
Sample size calculation Reported 0 1 0 7
Informed Consent Reported 0 3 15 19
Number of arms 2-arm 6 14 20 18
3-arm 4 2 2 2
Subjects
Eligibility criteria Clear 2 2 18 22
Diagnostic criteria Structured form 0 1 0 9
Diagnostic severity Rating scales 12 13 20 19
Methods
Randomization Adequate 4 2 0 11
Allocation Adequate 5 0 1 3
Primary hypothesis Adequate 0 4 2 12
Results
Baseline comparisons Adequate 4 11 11 21
Adverse effects Adequate 5 4 11 16
Dropout reasons Adequate 15 14 15 19
p value Adequate 6 7 10 18
Conclusions
Trial result Positive 7 15 12 13
Negative 10 6 8 6
Unclear 7 2 1 3
Consistency Yes 1 11 13 18
Dubious 14 10 7 4
No 9 2 1 0
All data are presented as the number (count) of trials per period, except the number of subjects, which is presented as mean and standard error.
(*)includes Schizophrenia, ‘‘Paraphrenia’’, ‘‘elderly patients with psychosis’’ and other types of non-affective psychosis.
(**)includes Maniac-Depressive Illness, Mania, and Bipolar Disorder.
doi:10.1371/journal.pone.0009479.t002
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further discuss some topics in which these changes impacted the
development of clinical trials and discuss future directions based
on these results.
First, some limitations should be addressed. One issue is that we
based our results on the reports; therefore it is possible that some
methodological flaws we encountered were due to lack of
reporting. Also, publication bias was a potential issue in our study
as we limited our study to articles published only in high-standard
journals.
We observed that the quality of abstract reporting improved
over the past 60 years. One possible explanation is that journal
editors and clinical researchers had noticed that reports of
statistics, randomization and baseline comparisons were poor
[44,45] and proposed a set of guidelines to improve the reporting
of clinical trials, which ultimately led to the CONSORT statement
[46]. However, our results showed that abstract reporting
improved significantly before CONSORT; on the other hand,
recent reviews [47,48] of abstract reporting in top impact-factor
journals showed improvement also after CONSORT and also that
many top journals had not been referring to CONSORT or
alternative abstract guidelines, or had referred to old CONSORT
versions. Thus, another possible reason for this improvement is
that the abstract gained more importance recently as it is openly
available in web databases, becoming an essential piece of
information to decide whether or not the full manuscript should
be read. In fact, frequently, only the abstract is read, thus
supporting its conciseness showing the main characteristics of
study design (the reader should understand how the main
hypothesis was tested by reading the abstract), main results
Table 3. Data analysis and study results.
Outcome variables Predictor variables
Year (continuous)
Year
(ordinal) Drug Class
Abstract reporting Level B (S.E.) p
x2o r
ANOVA p
x2o r
ANOVA p
Background Adequate (vs. Inadequate) 20.11(0.02) ,0.01 33.8 ,0.01 2.54 0.28
Methods Adequate (vs. Inadequate) 20.08 (0.02) ,0.01 19.4 ,0.01 5.4 0.07
Results Adequate (vs. Inadequate) 20.1 (0.02) ,0.01 37.1 ,0.01 1.6 0.45
Subjects section p
Eligibility Criteria Clear (vs. Unclear) 20.23 (0.05) ,0.01 35.4 ,0.01 4.03 0.13
Diagnostic Criteria Interview (vs. Structured) 0.15 (0.5) ,0.01 17.4 ,0.01 5.7 0.06
Diagnostic Severity Scales (vs. Judgment) 0.06 (0.02) ,0.01 66.3 ,0.01 4.56 0.11
Informed Consent Yes (vs. No) 0.17 (0.03) ,0.01 49.7 ,0.01 12.45 0.01
Sample Size Estimation Yes (vs. No) 0.14 (0.05) ,0.01 19.6 ,0.01 3.77 0.15
Number of Subjects(*) 2.58 (1.24) 0.04 3.06 0.03(*) 1.83 0.17
Study Design
Number of Arms 2 (vs. 3 and others) 20.08(0.02) ,0.01 25.8 ,0.01 5.08 0.08
Use of Placebo Yes (vs. No) 0.02(0.01) 0.13 5.7 0.13 9.8 0.01
Wash-out period Yes (vs. No) 0.05 (0.02) ,0.01 39.96 ,0.01 6.32 0.17
Centers Uni (vs. Multicentric) 0.06 (0.02) ,0.01 16.53 ,0.01 1.26 0.53
Intention-to-Treat Yes (vs. No) 0.15 (0.03) ,0.01 42.6 ,0.01 0.56 0.75
Methods section
Randomization Adequate (vs. Inadequate) 0.05 (0.02) 0.01 20.83 ,0.01 8.78 0.02
Allocation Adequate (vs. Inadequate) 20.02 (0.02) 0.39 6.8 0.08 7.96 0.02
Primary Hypothesis Adequate (vs. Inadequate) 21.4 (0.26) ,0.01 24.34 ,0.01 5.78 0.55
Results reporting
Baseline comparisons Adequate (vs. Inadequate) 0.08 (0.02) ,0.01 28.82 ,0.01 6.72 0.04
Adverse Effects Adequate (vs. Inadequate) 0.07 (0.02) ,0.01 19.37 ,0.01 2.91 0.23
Reasons for drop-outs Adequate (vs. Inadequate) 0.09 (0.03) 0.34 6.1 0.41 5.63 0.21
p value Adequate (vs. Inadequate) 0.11 (0.03) ,0.01 32.1 ,0.01 13.7 0.08
Test used Para (vs. Non-para) 0.05 (0.2) ,0.01 15.06 ,0.01 5.57 0.06
Conclusion section
Trial result Positive (vs. others) 20.02 (0.01) 0.16 10.23 0.11 14.3 0.06
Consistency Yes (vs. others) 20.01 (0.2) ,0.01 35.8 ,0.01 19.2 ,0.01
We used the logistic regression model to analyze the association between each outcome variable (treated as categorical data) and the predictor variable year (treated as
continuous data). Also, we used the Chi-square test or the Fisher’s exact test for the predictor variables year (when treated as ordinal data, divided in quartiles) and Drug
Class, treated as ordinal data, divided in mood stabilizers, antipsychotics and others (fluoxetine and diazepam).
(*)for number of subjects we used the one-way ANOVA. B (SE) represents B value and its standard deviation.
doi:10.1371/journal.pone.0009479.t003
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of findings, avoiding overstatements.
Moreover, more trials reported the eligibility criteria used,
confirmed the diagnostics with structured interviews rather
than clinical evaluation and used severity rating scales rather
than personal judgment on improvement. Using structured
questionnaires improves study validity and reliability – as they
are more sensitive to perform differential diagnoses [49] and
have more agreement between raters than unstructured
evaluations [50]. Reporting the eligibility criteria and using
Figure 4. Changes in abstract reporting over time. Blue, red, and green bars show the number of trials adequately reporting background,
methods and results in the abstract, respectively, at each period of time. The number of trials per period was 24 (1961 and earlier), 23 (1962–1974), 22
(1975–1989) and 22 (1990 and after).
doi:10.1371/journal.pone.0009479.g004
Figure 5. Changes in study design over time. Blue bars represent the number of trials performing two-arm studies; red bars are the trials
performing three-arm studies. Green bar represent studies using other designs.The number of trials per period was 24 (1961 and earlier), 23 (1962–
1974), 22 (1975–1989) and 22 (1990 and after).
doi:10.1371/journal.pone.0009479.g005
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targeted sample and thus to evaluate the generalizability of the
study results [51]. However, diagnostic criteria standardization
can also generate heterogeneous diagnostic groups. For
instance, according to DSM-IV criteria, there are 93 different
combinations of depressive symptoms [6], reflecting patients
with different characteristics that are in the same ‘‘depression
DSM-IV’’ classification.
Figure 6. Changes in study methodology over time (1). Blue bars represent the number of trials that had a placebo arm at each period of time.
Red bars represent the number of studies using intention-to-treat techniques. Green bars represent the number of studies that clearly reported their
eligibility criteria.The number of trials per period was 24 (1961 and earlier), 23 (1962–1974), 22 (1975–1989) and 22 (1990 and after).
doi:10.1371/journal.pone.0009479.g006
Figure 7. Changes in study methodology over time (2). Blue bars represent the number of trials that adequately reported randomization
methods at each period of time. Red bars represent the number of studies adequately reporting allocation methods. Green bars represent the studies
that adequately stated their primary hypothesis.The number of trials per period was 24 (1961 and earlier), 23 (1962–1974), 22 (1975–1989) and 22
(1990 and after).
doi:10.1371/journal.pone.0009479.g007
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PLoS ONE | www.plosone.org 10 March 2010 | Volume 5 | Issue 3 | e9479Figure 8. Changes in results reporting over time. Blue bars represent the number of studies that applied parametric tests in their primary
outcome at each time period. Red bars represent the number of studies reporting p values at each time period. Green bars represent the number of
studies fully reporting adverse effects at each time period.The number of trials per period was 24 (1961 and earlier), 23 (1962–1974), 22 (1975–1989)
and 22 (1990 and after).
doi:10.1371/journal.pone.0009479.g008
Figure 9. Study outcomes over time. The figure shows the number of studies in which the conclusion was positive (i.e., confirmed the primary
hypothesis) (blue bars), negative (did not confirm the primary hypothesis) (red bars) or unclear, when the authors did not present a clear conclusion/
interpretation of their results (green bars).The number of trials per period was 24 (1961 and earlier), 23 (1962–1974), 22 (1975–1989) and 22 (1990 and
after).
doi:10.1371/journal.pone.0009479.g009
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addressing drug efficacy either quantitatively (score reduction) or
qualitatively (response and remission rates). These rating scales are
also useful to screen and recruit patients, assess severity, define
predictors of response [52] and importantly, to compare the results
across different studies. Thus, psychometric scales grant more
precision when measuring outcomes. On the other hand, they
require proper training to gain satisfactory inter-rater reliability
[53] and also are limited. An example of its limitation can be seen
through the Hamilton Depression Rating Scale. This scale is
excessively weighted in anxiety and somatic symptoms but has
little coverage for important depression symptoms [7]. Therefore,
although diagnostic standardization certainly increased internal
validity, there is still a significant margin for more diagnostic
refinement.
Sample size increased over time, however this was marginally
significant and could be explained by one large trial with a very
large sample [28]. However, the number of multicentric studies
also increased, perhaps explaining this finding. In addition, more
trials performed (or reported) sample size calculations, which can
be explained by several reasons, such as: (1) ethical and
economical issues in enrolling more subjects than necessary for
the primary hypothesis; (2) statistical improvement over time,
allowing a more precise estimation of sample size; (3) increase in
scientific rigor over time, as researchers are demanded to state
their primary hypothesis a priori; (4) concern with negative results
due to lack of statistical power.
Regarding study design, we observed that recent trials favor
two-arm design while old trials favor three-arm and other designs.
Possible reasons are: (1) less prior knowledge on drug effects (e.g.,
carry-over effects); (2) sponsorship interest of pharmaceutical
companies on researching a specific drug and; (3) scarce use of
meta-analytic techniques that favor two-arm studies in the past. In
addition, we observed that newer trials performed more intention-
to-treat analysis, a method used to handle with differential
dropouts in treatment groups, increasing the internal validity of
the study [54].
Placebo use did not change and remained elevated over time.
Although a full review on placebo is beyond our scope, two aspects
are important: the ethical issues when considering the use of
informed consent and the statistical/methodological importance of
placebo in clinical trials. In 1970, Baastrup et al. [30] argued they
would not inform patients that lithium would be changed to
placebo because there was still uncertainty on its prophylactic
effects. The lack of the principle of autonomy can be seen in which
the patients themselves have the right to decide whether or not is
in their best interest to, for instance, stop taking a given drug.
Another important issue is that placebo response in comparison to
the active group has increased over time [55], which could
theoretically reflect an improvement in internal validity, as robust
studies are less susceptible to accidentally breaking blinding.
Nevertheless, some reasons explaining the past and present
elevated placebo use include: it maximizes assay sensitivity of a
trial; therefore amplifying the signal [56]; placebo-controlled
studies need smaller sample sizes [13] and the relatively low risk of
using placebo in psychiatric trials for short periods of time [57].
Regarding statistics, we observed that more trials reported p
values over time. This trend was also observed in a review of
statistical methods in rehabilitation literature [58], probably
reflecting more rigor in data reporting as well as more training
in clinical research. In fact, perhaps ‘‘forcing’’ the authors (through
structured reporting guidelines) to report p values contributed to
increase their understanding of statistical methods. This is an
important issue when the statistics is done by a third party
statistician. Also, we observed newer trials using more parametric
tests for the primary hypothesis. Parametric tests increase study
Figure 10. Reliability of study conclusions over time. The figure shows the number of studies in which the conclusion was consistent, i.e.,
supported by the results (blue bars); inconsistent (red bars), and dubious (green bars), when it depends on a particular interpretation of the data (for
instance, post-hoc analysis, multiple outcomes, etc).The number of trials per period was 24 (1961 and earlier), 23 (1962–1974), 22 (1975–1989) and 22
(1990 and after).
doi:10.1371/journal.pone.0009479.g010
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expressed in score changes rather than response/relapse rates;
therefore decreasing sample size requirements. However there is a
concern whether it is appropriate using parametric tests for
psychiatric rating scales, which are constructed by several items
whose range of symptoms assessed are not continuous, but ordinal
(e.g., questions about weight loss are usually divided in less than
0.5kg; between 0.5-1kg; more than 1kg).
Randomization techniques also improved over time; however
the overall number of adequate reporting was quite low, even for
newer trials. This is surprising, as inadequate methods of
randomization and allocation are considered major sources of
bias [59,60]. However, here there is the issue of trial quality vs.
reporting quality that is highly debated in the literature. For
instance, Devereaux et al. [61] contacted authors from 98
randomized controlled trials published after 1997 that failed to
report one or more of the RCT procedures. By asking the authors
of these trials, Deveraux et al. found that although many trials
failed to report some aspects of trial designs, the procedures were
indeed performed in almost all studies. On the other hand,
Liberati et al. [62] reviewed 119 trials published from 1963 to
1986 and concluded that the overall low methodological quality of
the trials (assessed through a score system) only mildly improved
after a re-checking with the authors; and Schulz et al. [63],
assessed trial quality in 250 RCTs; and found that poor quality is
related to bias. In addition, there is no method of choice in
assessing bias and trial quality [64].
Along these lines, we verified several aspects of study design
(baseline group comparisons; adverse effects reporting; dropout
reasons, type of statistical test used) to assess whether the
conclusions presented were consistent. Studies rated as ‘‘inconsis-
tent’’ were of quite low quality, while ‘‘consistent’’ studies had
good quality. Almost one third of the studies were rated of
‘‘dubious’’ quality in which we did not draw definite conclusions
due to incomplete reporting or tendentious data interpretation.
Because of that, we think that an important aim for manuscript
publication is to allow different researchers to replicate and thus to
test the results of the studies. This would allow readers to critically
interpret these studies. In order to do so, the authors must detail
carefully the methods of their experiments [65]. Also, there is no
reason to not fully report all aspects of the study design,
particularly at the present time when journal editors and reviewers
use structured checklists to assess complete reporting and the
authors are able to address missing points when reviewing their
papers. Finally the issue of space can always be resolved with
supplementary online publication (even pointing out the methods
section to a webpage with detailed methodology is now possible).
Importantly, our results show that newer trials reported more
conclusions in line with the results, thus reflecting gains in
reporting and quality.
Conclusion
The psychopharmacological revolution that has been observed
since 1949 brought significant challenges for psychiatric research,
a field that virtually lacked drug treatment at that time. Some
changes include the adoption of operational diagnostic criteria and
psychometrics as well as assimilation of novel breakthrough
methods of clinical trial research. As a result, clinical trial quality
of psychopharmacological studies has changed significantly during
the past 60 years in several aspects such as study design, sampling,
randomization, allocation, statistical methods, ethical aspects and
reporting. In fact, only the use of placebo remained stable in this
period. These changes have increased study efficiency and internal
validity by systematically detecting, addressing and eliminating
various sorts of bias. However, there is room further improvement
in the development of rating scales and more refined diagnostic
criteria as well as better reporting of some aspects of trial
methodology. Therefore, despite the significant advancements
observed with better designed and more reliable trials as compared
to the past, it is still uncertain that we have achieved the optimal
clinical trials methodology.
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